drugset / Trial / NCT02725086

Evaluation of Pharmacokinetic/Pharmacodynamic Properties and Safety of Leucostim® Compared to Neupogen® in Healthy Adult Volunteers

NCT02725086

Phase 1 Completed 56 enrolled Dong-A ST Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

A Randomized, Open-label, Two-way Crossover, Open-label Clinical Trial to Compare Pharmacokinetic/Pharmacodynamic Properties and Safety after Subcutaneous Administration of Leucostim® and Neupogen® in Healthy Adult Volunteers

Timeline

Start
2016-02
Primary completion
2016-04
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject filgrastim Protein / enzyme biologic 5 ug/kg Subcutaneous
Subject filgrastim Protein / enzyme biologic 10 ug/kg Subcutaneous

Indications

No indication recorded.